Tocqueville Asset Management L.P. Raises Holdings in Becton, Dickinson and Company $BDX

Tocqueville Asset Management L.P. increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 43.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,179 shares of the medical instruments supplier’s stock after acquiring an additional 36,393 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Becton, Dickinson and Company were worth $18,187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NewEdge Wealth LLC boosted its stake in shares of Becton, Dickinson and Company by 14.3% during the second quarter. NewEdge Wealth LLC now owns 1,930 shares of the medical instruments supplier’s stock valued at $292,000 after purchasing an additional 242 shares during the period. Compass Wealth Management LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter worth approximately $486,000. BOK Financial Private Wealth Inc. increased its stake in shares of Becton, Dickinson and Company by 7.3% in the second quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock worth $162,000 after buying an additional 73 shares during the period. Diversify Advisory Services LLC bought a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $552,000. Finally, Wealthfront Advisers LLC purchased a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $2,567,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BDX shares. Royal Bank Of Canada upped their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Price Performance

BDX opened at $187.82 on Thursday. The stock has a 50-day moving average price of $159.86 and a 200-day moving average price of $161.02. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market cap of $51.75 billion, a PE ratio of 56.57, a P/E/G ratio of 12.74 and a beta of 0.19. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.96.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 11,779 shares of company stock worth $1,974,669. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.